Bone Health Awareness Sale ends in 00days 00hrs 00min
← Learn

Dietary Silicon and Bone Density After Menopause: The Mineral Calcium Ads Never Mention

August 2, 2026 · Optimum Research Team
Dietary Silicon and Bone Density After Menopause: The Mineral Calcium Ads Never Mention

A 2004 analysis of 2,847 adults in the long running Framingham study found something that never made it into a calcium ad. The people eating the most dietary silicon carried hip bone density roughly 10 percent higher than the people eating the least, a bigger gap than calcium intake produced in the same dataset. Silicon is not a hormone and does not replace the estrogen signaling that the shilajit research addresses directly, but it appears to build the collagen scaffold that calcium needs somewhere to attach. Here is what the actual studies found, and where shilajit fits into the same mechanism.

What does dietary silicon actually do for bone?

What does dietary silicon actually do for bone?

Most women hear "bone mineral" and think of calcium alone. Silicon works earlier in the process, before any mineral gets laid down at all.

Bone is not simply calcium stacked into a shape. It is a collagen scaffold that calcium mineralizes onto, and the strength of the finished bone depends heavily on how that scaffold was built in the first place. Silicon appears to play a direct role in forming the collagen crosslinks that give the scaffold its structural integrity, according to a 2007 mechanism review in the Journal of Nutrition, Health and Aging.

Why the scaffold matters as much as the mineral

Short version, calcium without a strong scaffold is like pouring concrete without rebar. A few things follow from that framing:

  • Collagen forms the flexible structural matrix bone is built around
  • Silicon is implicated in the crosslinking that holds that matrix together
  • Calcium then mineralizes onto the finished scaffold, not the other way around
  • A weak scaffold can still take up calcium and still fracture more easily
  • This is why some women with normal calcium intake still see declining bone density

Shilajit's own bone research works on a different part of the same problem, the hormonal signal that tells cells to build in the first place, which is exactly why the two mechanisms are worth understanding side by side rather than as competitors.

What did the Framingham cohort data actually find?

What did the Framingham cohort data actually find?

Jugdaohsingh and colleagues published the silicon analysis in 2004, drawing on the Framingham Offspring cohort, one of the longest running and most cited population health studies in the United States. Among 2,847 adults, the researchers sorted participants by dietary silicon intake into five groups and compared bone mineral density across them.

The top fifth for silicon intake carried hip bone density that ran roughly 10 percent higher than the bottom fifth, a larger separation than calcium intake produced across the same 2,847 people. That is a striking number for a mineral almost nobody tracks or supplements deliberately.

Why a cohort finding is not the same as a trial

A cohort study measures what people already do and looks backward for a pattern. It cannot prove that silicon caused the higher bone density, only that the two moved together in a large, carefully measured population.

Reading it honestly means holding two things at once.

  • Framingham is observational, not a randomized placebo controlled trial
  • 2,847 adults is a genuinely large sample, not a small pilot
  • The association held even after researchers adjusted for other known factors
  • It does not tell you what dose of silicon supplementation would do
  • It is the reason researchers went looking for a placebo controlled trial next

How is silicon connected to the estrogen signal shilajit supports?

How is silicon connected to the estrogen signal shilajit supports?

A separate 2012 cohort out of Aberdeen, led by MacDonald and colleagues, found something that ties this entire mineral category into one story instead of three unrelated ones. Dietary silicon's relationship to bone health appeared to interact with a woman's estrogen status, meaning the two systems are not operating independently of each other.

That is the same estrogen signaling pathway at the center of the shilajit bone research, the mechanism that Pingali and colleagues (2022) tested directly in a 48 week double blind, placebo controlled trial in 60 postmenopausal women. Every woman in the treatment group saw bone density increase at both the spine and hip, while the placebo group kept losing ground, with zero serious adverse events reported.

Where shilajit fits into the silicon story

Shilajit does not add estrogen to the body. It is not a hormone. What the fulvic acid inside it appears to support is the body's own estrogen signaling, the instruction layer that tells bone cells to rebuild. Silicon appears to work downstream of that same signal, helping form the collagen scaffold the instruction is acting on.

Calcium alone Silicon (bamboo silica) Shilajit
What it addresses Raw mineral supply Collagen scaffold formation The estrogen signal that drives rebuilding
Strongest human evidence Mixed across decades of trials 1 placebo controlled RCT (ch-OSA) 48 week RCT, density rose at spine and hip
Type of evidence Trial data, results vary RCT plus a 2,847-person cohort RCT with zero adverse events reported
Works on The building material The frame the material attaches to The order to start building

None of these three replace each other. They sit at different points in the same construction process, which is the reasoning behind combining shilajit with bamboo silica and pearl powder in a single Trifecta formula rather than betting on one mineral alone.

What did the placebo controlled silicon trial actually show?

Framingham is a cohort. Spector and colleagues (2008) ran an actual placebo controlled trial, the strongest human evidence in the silicon and bone category, in osteopenic women given a silicon compound called ch-OSA alongside calcium and vitamin D, compared against calcium and vitamin D alone.

The result was not a dramatic reversal. It was a preservation. The group receiving the silicon compound held steady on a marker of bone formation called PINP, while the placebo group's PINP declined over the course of the trial. Holding a marker steady while an untreated group loses ground is a real, measurable effect, even if it reads less dramatically than a number that climbs.

Bamboo silica versus ch-OSA, an honest note on bioavailability

Here is the caveat worth knowing first. Not every silicon source performs the same way.

  • Spector's trial used ch-OSA, not bamboo silica specifically
  • Ch-OSA has roughly 50 percent or higher bioavailability per milligram
  • Bamboo silica runs lower, roughly 15 to 30 percent per milligram
  • Formulas built around bamboo silica typically use a higher elemental dose to compensate
  • A separate 2010 pilot in postmenopausal women using silicon rich mineral water also raised bone formation markers, supporting the mechanism through a third delivery method

Reading all three studies together, the cohort, the trial, and the pilot, tells a more consistent story than any single one on its own. Dietary and supplemental silicon shows up again and again on the formation side of the bone equation, even though the silicon research alone stays smaller in scale than the shilajit density trial.

Common questions about silicon and bone after menopause

Does silicon build bone by itself?

The evidence supports silicon as a structural cofactor, not a standalone bone builder. It appears to help form the collagen scaffold that calcium mineralizes onto. The Framingham cohort found higher silicon intake tracked with higher hip bone density, and a placebo controlled trial found a silicon compound preserved a bone formation marker that declined on placebo, but no trial shows silicon alone reverses osteoporosis the way the shilajit research does.

Is bamboo silica as well studied as the silicon used in the research?

No, and this is worth saying plainly. Most of the strongest human evidence, including the placebo controlled Spector 2008 trial, used a compound called ch-OSA, not bamboo silica. Bamboo silica has lower per milligram bioavailability, roughly 15 to 30 percent versus 50 percent or more for ch-OSA, which is why formulas built around bamboo silica typically use a higher dose.

How does silicon connect to shilajit and estrogen?

A 2012 Aberdeen cohort study found that dietary silicon's relationship to bone health interacted with estrogen status. That is the same estrogen signaling pathway the shilajit research addresses directly. Pingali and colleagues found that a 48 week course of shilajit increased bone density at the spine and hip in postmenopausal women, the flagship human evidence in this entire mineral category.

Is the Framingham silicon finding proof that silicon prevents fractures?

No. Framingham is an observational cohort, meaning researchers measured what people already ate and compared their bone density afterward. It shows a strong association, not proof of cause and effect. It is real data from 2,847 adults, but it carries a different weight than a placebo controlled trial.

What foods contain dietary silicon?

Whole grains, leafy greens, and beer are among the higher silicon foods in a typical diet, though intake varies enormously by what a person actually eats day to day. That variability is part of why the Framingham researchers were able to compare a meaningful range of intake levels across their study population.

Optimum Shilajit box

The mineral that ties the whole scaffold together

Optimum Trifecta combines shilajit, bamboo silica, and pearl powder, sourced from the Altai mountains, tested by an independent lab for heavy metals on every batch, and shipped as a box of tablets, not a loose powder. If you want the formula built around this exact research, here is .

See Optimum Shilajit Trifecta

Sources

  1. Jugdaohsingh R, et al. Dietary silicon intake and absorption. Bone mineral density and silicon intake in the Framingham Offspring cohort. https://pubmed.ncbi.nlm.nih.gov/14969400/
  2. MacDonald HM, et al. Dietary silicon interacts with oestrogen to influence bone health in an observational cohort study. https://pubmed.ncbi.nlm.nih.gov/22173054/
  3. Spector TD, et al. Choline-stabilized orthosilicic acid supplementation and bone turnover markers in osteopenic women, a randomized controlled trial. https://pubmed.ncbi.nlm.nih.gov/18547426/
  4. Li W, et al. Silicon rich mineral water and bone formation markers in postmenopausal women, a pilot study. https://pmc.ncbi.nlm.nih.gov/articles/PMC2967495/
  5. Pingali U, et al. Effect of standardised shilajit on bone mineral density in postmenopausal women, a 48 week double blind randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/35933897/